βIIPKC and εPKC isozymes as potential pharmacological targets in cardiac hypertrophy and heart failure.
Ferreira
Julio Cesar Batista
JC
Department of Chemical and Systems Biology, Stanford University School of Medicine, CCSR, Rm 3145A, 269 Campus Drive, Stanford, CA 94305-5174, USA.
Brum
Patricia Chakur
PC
Mochly-Rosen
Daria
D
D000818:Animals; D006332:Cardiomegaly / Q000188:drug therapy* / Q000201:enzymology; D006333:Heart Failure / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009206:Myocardium / Q000201:enzymology*; D011493:Protein Kinase C / Q000378:metabolism*; D064546:Protein Kinase C beta; D051744:Protein Kinase C-epsilon / Q000378:metabolism*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
D007527:Isoenzymes; D047428:Protein Kinase Inhibitors; D011493:Protein Kinase C; D064546:Protein Kinase C beta; D051744:Protein Kinase C-epsilon